Free Newsletter
Schering anesthesia med makes Euro-debut
Free newsletter via e-mail
Tools
Schering-Plough has launched its anesthesia-reversal drug Bridion in Sweden, with plans to inaugurate the drug in the U.K. and Germany soon. Known generically as sugammadex, the drug was rejected for U.S. sale by the FDA in August, on concerns about allergic reactions. The agency said it may ask for more data on those reactions. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: